Q&A: Dana-Farber's Paul Morrison on Running a Helicos Sequencer in a Core Facility
October 13, 2009
Q&A: Dana-Farber's Paul Morrison on Running a Helicos Sequencer in a Core Facility
The director of the Molecular Biology Core Facilities at the Dana-Farber Cancer Institute discusses his experience with the system, and how it compares to other platforms.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Helicos Reports $1.1M in Q3 Revenue; Rules Out Company Sale for Now as Prospects Improve
November 10, 2009 / In Sequence - Helicos Installs Five Sequencers in Q3; Continues Talks with 'Multiple Strategic Parties'
October 27, 2009 / In Sequence - Correlagen to Launch Genetic Cardiovascular Disease Assay on Helicos Platform This Month
October 6, 2009 / In Sequence - Correlagen Purchases Helicos Instrument to Develop New Genetic Tests
September 29, 2009 / In Sequence - Helicos Hires Investment Bank to Advise on 'Strategic Alternatives,' Clarifies Instrument Placements
September 8, 2009 / In Sequence